AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10999124 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E levels in Group I
Number of subjects: 34
Study 10999124 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E levels in Group II
Number of subjects: 34
Study 10999124 — intervention group
Group type: COMPARATOR
Intervention: Lipid peroxide levels in Group II
Number of subjects: 34
Study 7588587 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-controlled epilepsy
Number of subjects: 494
Study 7588587 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 494
Study 1524655 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 mg/kg)
Number of subjects: 7
Study 1524655 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced haloperidol (0.5 mg/kg)
Number of subjects: 7
Study 1524655 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (10 mg) twice daily for 4 weeks
Number of subjects: 7
Study 1524655 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐dealkylation pathway
Number of subjects: 7
Study 3886566 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem alone
Number of subjects: 70
Study 3886566 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem in combination with diuretics
Number of subjects: 70
Study 3886566 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem in combination with other drugs
Number of subjects: 70
Study 31295074 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm-disrupting gel (BlastX) plus debridement (standard of care)
Number of subjects: 0
Study 31295074 — intervention group
Group type: COMPARATOR
Intervention: Triple-antibiotic maximum-strength ointment (standard of care)
Number of subjects: 0
Study 31295074 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to biofilm-disrupting gel after 4 weeks of standard care
Number of subjects: 0
Study 27655525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with broccoli
Number of subjects: 13
Study 27655525 — intervention group
Group type: COMPARATOR
Intervention: Mashed potato alone
Number of subjects: 13
Study 27655525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with broccoli fibre
Number of subjects: 13
Study 27655525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with cellulose
Number of subjects: 13
Study 27258230 — intervention group
Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 215
Study 25293665 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy
Number of subjects: 566
Study 25293665 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 566
Study 22240359 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheohaemapheresis (separator Cobe Spectra + Evaflux filter)
Number of subjects: 72
Study 22240359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 20650346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (750 mg, 3 times per day) 30 minutes before meals
Number of subjects: 12
Study 20650346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18365858 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg (CEE)
Number of subjects: 100
Study 18365858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 100
Study 18365858 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg (E(2)/NETA)
Number of subjects: 100
Study 18365858 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 60 mg
Number of subjects: 100
Study 18365858 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 100
Study 16181890 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive surgical and endovascular approach for aortic arch repair
Number of subjects: 0
Study 16181890 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular intervention with retrograde stent-graft placement
Number of subjects: 0
Study 12095385 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir, 300 mg twice per day, while continuing all other antiretroviral therapy (n = 54)
Number of subjects: 111
Study 12095385 — intervention group
Group type: COMPARATOR
Intervention: Continuing all antiretroviral therapy (n = 57)
Number of subjects: 111
Study 9501885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 336
Study 9501885 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 336
Study 7836531 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% non-heat-treated serum
Number of subjects: 135
Study 7836531 — intervention group
Group type: COMPARATOR
Intervention: 10% heat-treated serum
Number of subjects: 135
Study 3169489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin (15 g added to meal)
Number of subjects: 9
Study 3169489 — intervention group
Group type: COMPARATOR
Intervention: Methylcellulose (15 g added to meal, control)
Number of subjects: 9
Study 31778465 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual data presentation
Number of subjects: 0
Study 30201324 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg.kg−1 of dexmedetomidine (high Dex group)
Number of subjects: 90
Study 30201324 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 μg.kg−1 of dexmedetomidine (low Dex group)
Number of subjects: 90
Study 30201324 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo group)
Number of subjects: 90
Study 28277138 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg carnitine supplements
Number of subjects: 60
Study 28277138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25787990 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA enteral feeds (≈1% total fatty acids)
Number of subjects: 626
Study 25787990 — intervention group
Group type: COMPARATOR
Intervention: Standard-DHA enteral feeds (≈0.3% total fatty acids)
Number of subjects: 626
Study 23159100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive statin therapy
Number of subjects: 248
Study 23159100 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-3 levels
Number of subjects: 248
Study 23159100 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-1 and MMP-2 levels
Number of subjects: 248
Study 23159100 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-3 levels at follow-up
Number of subjects: 248
Study 23159100 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2 and MMP-3 levels at follow-up
Number of subjects: 248
Study 20462570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) plus treatment as usual (TAU)
Number of subjects: 106
Study 20462570 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 106
Study 19178808 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible reinforced laryngeal mask airway (FRLMA)
Number of subjects: 60
Study 19178808 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 60
Study 16817556 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded dermal tuberculin test using 100%, 25%, 5%, and 1% tuberculin solution via prick test
Number of subjects: 0
Study 12694144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5 micro g.ml‐1
Number of subjects: 36
Study 12694144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1.0 micro g.ml‐1
Number of subjects: 36
Study 12694144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1.5 micro g.ml‐1
Number of subjects: 36
Study 12694144 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline 2.0 micro g.ml‐1 (standard mixture)
Number of subjects: 36
Study 10896687 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic group (Alzheimer's disease with psychotic symptoms)
Number of subjects: 20
Study 10896687 — intervention group
Group type: COMPARATOR
Intervention: Non-psychotic group (Alzheimer's disease without psychotic symptoms)
Number of subjects: 20
Study 9199908 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 58
Study 9199908 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 58
Study 8355938 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dissection
Number of subjects: 48
Study 8355938 — intervention group
Group type: COMPARATOR
Intervention: Abdominal surgery without vaginal dissection
Number of subjects: 48
Study 3794300 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 40 micrograms HBsAg (months 0, 1, 6)
Number of subjects: 88
Study 3794300 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of 10 micrograms HBsAg (healthy controls)
Number of subjects: 88
Study 3794300 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 doses of 40 micrograms HBsAg (monthly intervals)
Number of subjects: 88
Study 3794300 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 doses of 20 micrograms HBsAg (monthly)
Number of subjects: 88
Study 29500217 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (up to 2 g/day)
Number of subjects: 86
Study 29500217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 28112286 — intervention group
Group type: EXPERIMENTAL
Intervention: Training EMS personnel in recognizing and initiating treatment in the prehospital setting with early administration of antibiotics
Number of subjects: 0
Study 28112286 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25368541 — intervention group
Group type: EXPERIMENTAL
Intervention: Study diet (Oxepa®; Abbott Japan) containing EPA, DHA, GLA, and antioxidants
Number of subjects: 62
Study 25368541 — intervention group
Group type: COMPARATOR
Intervention: General control diet (Ensure® H; Abbott Japan)
Number of subjects: 62
Study 22518369 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting oral morphine 30 mg orally twice daily for three days
Number of subjects: 200
Study 22518369 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 200
Study 20190259 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsh PK model with k(e0)=0.26 min(‐1) (Group M)
Number of subjects: 60
Study 20190259 — intervention group
Group type: EXPERIMENTAL
Intervention: Schnider PK model with fixed k(e0)=0.456 min(‐1) (Group S1)
Number of subjects: 60
Study 20190259 — intervention group
Group type: EXPERIMENTAL
Intervention: Schnider PK model with k(e0) adapted to a fixed time‐to‐peak effect=1.6 min (Group S2)
Number of subjects: 60
Study 18279691 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Y Jelly
Number of subjects: 6
Study 18279691 — intervention group
Group type: EXPERIMENTAL
Intervention: Replens
Number of subjects: 6
Study 18279691 — intervention group
Group type: COMPARATOR
Intervention: Ambulation
Number of subjects: 6
Study 18279691 — intervention group
Group type: COMPARATOR
Intervention: Parity
Number of subjects: 6
Study 18279691 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Index (BMI)
Number of subjects: 6
Study 16007008 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chitosan on 0.2% HCl in combination with methylene blue and IR laser beam (study group)
Number of subjects: 68
Study 16007008 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (control group)
Number of subjects: 68
Study 12605026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 12605026 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cariporide
Number of subjects: 53
Study 12605026 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg cariporide
Number of subjects: 53
Study 12605026 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg cariporide
Number of subjects: 53
Study 12605026 — intervention group
Group type: EXPERIMENTAL
Intervention: All cariporide groups (20 mg, 80 mg, 120 mg)
Number of subjects: 53
Study 12605026 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 53
Study 10382587 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA %S
Number of subjects: 24
Study 10382587 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐h CIGMA %S
Number of subjects: 24
Study 10382587 — intervention group
Group type: EXPERIMENTAL
Intervention: FSIVGTT‐MinMod
Number of subjects: 24
Study 10382587 — intervention group
Group type: COMPARATOR
Intervention: ITT
Number of subjects: 24
Study 10382587 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-CIGMA with immunoreactive insulin
Number of subjects: 24
Study 9147928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatinum (CDP) with 3-drug protocol (MTX, CDP, ADM)
Number of subjects: 149
Study 9147928 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatinum (CDP) with 3-drug protocol (MTX, CDP, ADM)
Number of subjects: 149
Study 9147928 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatinum (CDP) with 4-drug protocol (MTX, CDP, ADM, IFO)
Number of subjects: 149
Study 9147928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatinum (CDP) with 4-drug protocol (MTX, CDP, ADM, IFO)
Number of subjects: 149
Study 9147928 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug protocol (MTX, CDP, ADM, IFO)
Number of subjects: 149
Study 1927982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (Peridex)
Number of subjects: 34
Study 1927982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7270654 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised exercise program to improve physical fitness
Number of subjects: 32
Study 7270654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study 31550774 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Number of subjects: 265
Study 31550774 — intervention group
Group type: COMPARATOR
Intervention: Traditional paclitaxel
Number of subjects: 265
Study 29101258 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke preparedness campaign (exposed group)
Number of subjects: 1622
Study 29101258 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexposed)
Number of subjects: 1622
Study 29101258 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome - Stroke recognition (exposed group)
Number of subjects: 1622
Study 26724101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol at 2-5 mg/kg per day, up-titrated to a maximum of 25 mg/kg or 50 mg/kg per day depending on study site.
Number of subjects: 214
Study 26724101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 214
Study 23871320 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration plus laparoscopic cholecystectomy (LCBDE+LC)
Number of subjects: 120
Study 23871320 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy (ERCP+LC)
Number of subjects: 120
Study 21668681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (Tamiflu(®); Roche) 75 mg once daily prophylaxis
Number of subjects: 56
Study 21668681 — intervention group
Group type: COMPARATOR
Intervention: Seasonal influenza vaccine (Fluviral(®))
Number of subjects: 56
Study 21668681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir prophylaxis
Number of subjects: 56
Study 18445082 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with a vaccine containing 50% of the wild grasses Trisetum paniceum and Dactylis glomerata, administered with a schedule of 0.1 and 0.2 mL at day 1, followed by 0.3 and 0.5 mL at day 7, 0.5 mL after 2 weeks, and 0.5 mL monthly, totaling a mean of 6.5 injections over 2.3 months.
Number of subjects: 33
Study 18445082 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) with no intervention reported.
Number of subjects: 33
Study 16807413 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine-lowering treatment (daily supplement containing folate 1000 microg, B12 500 microg, and B6 10 mg)
Number of subjects: 276
Study 16807413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 12897990 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture
Number of subjects: 23
Study 10740555 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional diamorphine 2.5 mg i.v.
Number of subjects: 14
Study 9206054 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron, 5 mg)
Number of subjects: 30
Study 9206054 — intervention group
Group type: COMPARATOR
Intervention: Kytril (granisetron, 3 mg)
Number of subjects: 30
Study 1317641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 1 mg of gemeprost every 3 h
Number of subjects: 50
Study 1317641 — intervention group
Group type: COMPARATOR
Intervention: 4 x 1 mg of gemeprost every 6 h
Number of subjects: 50
Study 1317641 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h gemeprost group
Number of subjects: 50
Study 1317641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 50
Study 3975430 — intervention group
Group type: EXPERIMENTAL
Intervention: BW245C (150 micrograms, 6-hourly for 5 days)
Number of subjects: 6
Study 3975430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29431471 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein hypocaloric diet (2.0 g protein/kg/d)
Number of subjects: 17
Study 29431471 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein hypocaloric diet (1.0 g protein/kg/d)
Number of subjects: 17
Study 29431471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (higher protein and standard protein)
Number of subjects: 17
Study 28088768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam
Number of subjects: 1033
Study 26303818 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIC) - three cycles of 5 min ischaemia followed by 5 min reperfusion in the upper arm immediately before surgery
Number of subjects: 69
Study 26303818 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 69
Study 23169759 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR)
Number of subjects: 47
Study 21683336 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-μm flap
Number of subjects: 368
Study 21683336 — intervention group
Group type: COMPARATOR
Intervention: 100-μm flap
Number of subjects: 368
Study 19783371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion (0.35mg/kg/h, not to exceed 25mg/h over a 4h period) for 10 days
Number of subjects: 0
Study 19783371 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (normal saline) for 10 days
Number of subjects: 0
Study 16523185 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAPS intervention program
Number of subjects: 954
Study 16523185 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 954
Study 12641538 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) plus vitamin B6 (250 mg)
Number of subjects: 158
Study 12641538 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 158
Study 10858389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (apneas and oxygen desaturations)
Number of subjects: 226
Study 9174206 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 875 mg orally
Number of subjects: 12
Study 9174206 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 1 g intramuscularly
Number of subjects: 12
Study 1388195 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 16
Study 1388195 — intervention group
Group type: COMPARATOR
Intervention: Untreated HIV-infected control patients
Number of subjects: 16
Study 4023620 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of secretin for 60 min
Number of subjects: 103
Study 4023620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of secretin and cholecystokinin for another 60 min
Number of subjects: 103
Study 4023620 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker concentrations in the aspirate
Number of subjects: 103
Study 29782468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriotherapy with Lactobacillus strains (Lactobacillus fermentum, Lactobacillus delbrueckii, Lactobacillus plantarum, Lactobacillus salivarius) for 6 months
Number of subjects: 100
Study 29782468 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 100
Study 26625946 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day paediatric simulation course
Number of subjects: 61
Study 26625946 — intervention group
Group type: COMPARATOR
Intervention: Standard paediatric attachment (control group)
Number of subjects: 61
Study 24762804 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV primary screening
Number of subjects: 8873
Study 24762804 — intervention group
Group type: COMPARATOR
Intervention: Cytology screening
Number of subjects: 8873
Study 24762804 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV type 16 positive at baseline
Number of subjects: 8873
Study 24762804 — intervention group
Group type: EXPERIMENTAL
Intervention: HC2 cut-off of RLU/Co ≥ 2
Number of subjects: 8873
Study 24762804 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination with Cervarix™
Number of subjects: 8873
Study 24762804 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary HPV screening
Number of subjects: 8873
Study 22283360 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM) with live nursing visits and video-based nursing visits
Number of subjects: 328
Study 22283360 — intervention group
Group type: COMPARATOR
Intervention: Live nursing visits only (Control)
Number of subjects: 328
Study 22283360 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 328
Study 20174905 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (V) 160 mg once daily
Number of subjects: 74
Study 20174905 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (O) 20 mg once daily
Number of subjects: 74
Study 20174905 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (A) 10 mg once daily
Number of subjects: 74
Study 18344941 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG (9 mg/kg ATG Fresenius S)
Number of subjects: 79